

MEDICAL CANNABIS AND MEDICAL RESEARCH BY CONDITION:

Anxiety – Learn More:

- Anxiety & Panic Disorders Health Center: Anxiety Disorders. (n.d.). WebMD. Retrieved from <http://www.webmd.com/anxiety-panic/guide/mental-health-anxiety-disorders>.
- Anxiety Disorders. (2015, May). National Institute of Mental Health. Retrieved from <http://www.nimh.nih.gov/health/topics/anxiety-disorders/index.shtml>.
- Bluett, R.J., Gamble-George, J.C., Hermanson, D.J., Hartley, N.D., Marnett, L.J., and Patel, S. (2014). Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. *Translational Psychiatry*, 4(7), e408. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119220/>.
- García-Gutiérrez, M.S., García-Bueno, B., Zoppi, S., Leza, J.C., and Manzanares, J. (2012, February). Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alternations in GABAA *British Journal of Pharmacology*, 165(4), 951-964. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312491/>.
- García-Gutiérrez, M.S., and Manzanares, J. (2011, January). Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of

- alprazolam in mice. *Journal of Pharmacology*, 25(1), 111-120. Retrieved from <http://journals.sagepub.com/doi/pdf/10.1177/0269881110379507>.
- Moreira, F.A., Kaiser, N., Monory, K., and Lutz, B., (2008, January). Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. *Neuropharmacology*, 54(1), 141-50. Retrieved from <http://www.sciencedirect.com/science/article/pii/S0028390807002146>.
 - Walsh, Z., Gonzalez, R., Crosby, K., Thiessmen, M.S., Carroll, C., and Bonn-Miller, M.O. (2016, October 12). Medical cannabis and mental health: A guided systematic review. *Clinical Psychology Review*, 51, 15-29. Retrieved from <http://www.sciencedirect.com/science/article/pii/S0272735816300939>.

Pain – Learn More:

- About the Epidemic. (n.d.). U.S. Department of Health & Human Services. Retrieved from <https://www.hhs.gov/opioids/about-the-epidemic/>.
- Abrams, D.I., Couey, P., Shade, S.B., Kelly, M.E., and Benowitz, N.L. (2011, December). Cannabinoid–Opioid Interaction in Chronic Pain. *Clinical Pharmacology & Therapeutics*, 90(6), 844-51. Retrieved from <http://onlinelibrary.wiley.com/wol1/doi/10.1038/clpt.2011.188/full>.
- Borgelt, L.M., Franson, K.L., Nussbaum, A.M., Wang, G.S. (2013, February). The pharmacologic and clinical effects of medical cannabis. *Pharmacotherapy*, 33(2), 195-209. Retrieved from <http://onlinelibrary.wiley.com/wol1/doi/10.1002/phar.1187/full>.
- Bosshard, S.C., Grandjean, J., Schroeter, A., Baltes, C., Zeilhofer, H.U., and Rudin, M. (2012, July). Hyperalgesia by low doses of the local anesthetic lidocaine involves cannabinoid signaling: An fMRI study in mice. *Pain*, 153(7), 1450-8. Retrieved from <http://journals.lww.com/pain/pages/articleviewer.aspx?year=2012&issue=07000&article=00019&type=abstract>.

- Burston, J.J., Sager, D.R., Shao, P., Bai, M., King, E., Brailsford, L., Turner, J.M., Hathway, G.J., Bennett, A.J., Walsh, D.A., Kendall, D.A., Lichtman, A., and Chapman, V. (2013, November 25). Cannabinoid CB2 Receptors Regulate Central Sensitization and Pain Responses Associated with Osteoarthritis of the Knee Joint. *PLOS One*, 8(11), e80440. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840025/>.
- Carlini, B.H., Garrett, S.B., and Carter, G.T. (2015, September). Medicinal Cannabis: A Survey Among Health Care Providers in Washington State. *The American Journal of Hospice & Palliative Care*. Retrieved from <http://journals.sagepub.com/doi/pdf/10.1177/1049909115604669>.
- Cottler, L. B., Abdallah, A. B., Cummings, S. M., Barr, J., Banks, R., & Forchheimer, R. (2011). Injury, Pain, and Prescription Opioid Use Among Former National Football League (NFL) Players. *Drug and Alcohol Dependence*, 116(1-3), 188–194. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095672/>.
- Cravatt, B.F., and Lichtman, A.H. (2004, October). The endogenous cannabinoid system and its role in nociceptive behavior. *Journal of Neurobiology*, 61(1), 149-60. Retrieved from <http://onlinelibrary.wiley.com/doi/10.1002/neu.20080/epdf>.
- Emerich, B.L., Ferreira, R.C.M., Cordeiro, M.N., Borges, M.H., Pimenta, A.M.C., Figueiredo, S.G., Duarte, I.D.G., and de Lima, M.E. (2016). δ -Ctenitoxin-Pn1a, a Peptide from *Phoneutria nigriventer* Spider Venom, Shows Antinociceptive Effect Involving Opioid and Cannabinoid Systems, in Rats. *Toxins*, 8(4), 106. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848632/>.
- Fine, P.G., and Rosenfeld, M.J. (2014). Cannabinoids for Neuropathic Pain. *Current Pain and Headache Reports*, 18(10), 451. Retrieved from <http://link.springer.com/article/10.1007%2Fs11916-014-0451-2>.
- Gerak, L.R., and France, C.P. (2016, May). Combined treatment with morphine and Δ^9 -tetrahydrocannabinol (THC) in rhesus monkeys: antinociceptive tolerance and withdrawal. *The Journal of Pharmacology and Experimental Therapeutics*, 357(2), 357-66. Retrieved from <http://jpet.aspetjournals.org/content/357/2/357.long>.

- Hirsh, A.T., Kratz, A.L., Engel, J.M., and Jensen, M.P. (2011). Survey Results of Pain Treatments in Adults with Cerebral Palsy. *American Journal of Physical Medicine & Rehabilitation / Association of Academic Physiatrists*, 90(3), 207–216. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036542/>.
- Kinsey, S.G., Mahadevan, A., Zhao, B., Sun, H., Naidu, P. S., Razdan, R.K., Selley, D.E., Damaj, M.I., and Lichtman, A.H. (2011). The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. *Neuropharmacology*, 60(2-3), 244–251. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021987/>.
- Lee, M.C., Ploner, M., Wiech, K., Bingel, U., Wanigasekera, V., Brooks, J., Menon, D.K., and Tracey, I. (2013, January). Amygdala activity contributes to the dissociative effect of cannabis on pain perception. *Pain*, 154(1), 124-134. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549497/>.
- Li, M.H., Suchland, K.L., and Ingram, S. (2016, December). Compensatory activation of cannabinoid CB2 receptor inhibition of GABA release in the rostral ventromedial medulla (RVM) in inflammatory pain. *Journal of Neuroscience*, 1310-16. Retrieved from <http://www.jneurosci.org/content/early/2016/12/09/JNEUROSCI.1310-16.2016.1>.
- Pain: Hope Through Research (2015, September 4). National Institute of Neurological Disorders and Stroke. Retrieved from <https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Pain-Hope-Through-Research>.
- Perron, B.E., Bohnert, K., Perone, A.K., Bonn-Miller, M.O., & Ilgen, M. (2015). Use of Prescription Pain Medications Among Medical Cannabis Patients: Comparisons of Pain Levels, Functioning, and Patterns of Alcohol and Other Drug Use. *Journal of Studies on Alcohol and Drugs*, 76(3), 406–413. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440298/>.
- Roberts, J.D., Gennings, C., and Shih, M. (2006, January). Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. *European Journal of*

Pharmacology, 530(1-2), 54-8. Retrieved

from <http://www.sciencedirect.com/science/article/pii/S001429990501215X>.

- Russo, E.B., and Hohmann, A.G. (2012, September 22). Role of cannabinoids in pain management. *Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches*, 181-197. Retrieved from http://link.springer.com/chapter/10.1007%2F978-1-4614-1560-2_18.
- Staahl, C., Olesen, A.E., Andresen, T., Arendt-Nielsen, L., and Drewes, A.M. (2009, September). Assessing efficacy of non-opioid analgesics in experimental pain models in healthy volunteers- an updated review. *British Pharmacological Society*, 68(3), 322-341. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2766472/>.
- Wakley, A.A., Wiley, J.L., and Craft, R.M. (2014). Sex differences in antinociceptive tolerance to delta-9-tetrahydrocannabinol in the rat. *Drug and Alcohol Dependence*, 143, 22–28. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161674/>.
- Ware, M.A., Doyle, C.R., Woods, R., Lynch, M.E., and Clark, A.J. (2003, March). Cannabis use for chronic non-cancer pain: results of a prospective survey. *Pain*, 102(1-2). Retrieved from http://journals.lww.com/pain/Abstract/2003/03000/Cannabis_use_for_chronic_non_cancer_pain_results.23.aspx.
- Ware, M.A., Wang, T., Shapiro, S., and Collet, J.P. (2015, September 15). Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). *The Journal of Pain*. Retrieved from [http://www.jpain.org/article/S1526-5900\(15\)00837-8/fulltext](http://www.jpain.org/article/S1526-5900(15)00837-8/fulltext).
- Webb, C. W., & Webb, S. M. (2014). Therapeutic Benefits of Cannabis: A Patient Survey. *Hawai'i Journal of Medicine & Public Health*, 73(4), 109–111. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998228/>.
- Wilsey, B., Marcotte, T. D., Deutsch, R., Gouaux, B., Sakai, S., & Donaghe, H. (2013). Low Dose Vaporized Cannabis Significantly Improves Neuropathic Pain. *The Journal of Pain : Official Journal of the American Pain Society*, 14(2), 136–148. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566631/>.

- Wilsey, B., Marcotte, T.D., Deutsch, R., Zhao, H., Prasad, H., and Phan, A. (2016) An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain from Spinal Cord Injury and Disease. *Journal of Pain*, doi: 10.1016/j.pain.2016.05.010. Retrieved from [http://www.jpain.org/article/S1526-5900\(16\)30072-4/fulltext](http://www.jpain.org/article/S1526-5900(16)30072-4/fulltext).
- Woodhams, S.G., Sagar, D.R., Burston, J.J., and Chapman, V. (2015). The role of the endocannabinoid system in pain. *Handbook of Experimental Pharmacology*, 227, 119-43. Retrieved from http://link.springer.com/chapter/10.1007%2F978-3-662-46450-2_7.

Depression – Learn More:

- Anderson, D.M., Rees, D.I., and Sabia, J.J. (2012, January 7). High on Life? Medical Marijuana Laws and Suicide. *Cato Institute*, 17. Retrieved from http://object.cato.org/sites/cato.org/files/pubs/pdf/research_brief_17.pdf.
- Ashton, C.H., and Moore, P.B. (2011, October). Endocannabinoid system dysfunction in mood and related disorders. *Acta Psychiatrica Scandinavica*, 124(4), 250-61. Retrieved from <http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0447.2011.01687.x/full>.
- Bricker, J.B., Russo, J., Stein, M.B., Sherbourne, C., Craske, M., Schraufnagel, T.J., and Roy-Byrne, P. (2007). Does occasional cannabis use impact anxiety and depression treatment outcomes?: Results from a randomized effectiveness trial. *Depression and Anxiety*, 24(6), 392-8. Retrieved from <http://onlinelibrary.wiley.com/doi/10.1002/da.20248/pdf>.
- Denson, T.F., and Earleywine, M. (2006, April). Decreased depression in marijuana users. *Addictive Behaviors*, 31(4), 738-742. Retrieved from <http://www.sciencedirect.com/science/article/pii/S0306460305001577>.
- Depression (major depressive disorder). (2015, July 22). Mayo Clinic. Retrieved from <http://www.mayoclinic.org/diseases-conditions/depression/basics/definition/con-20032977>.

- Gorzalka, B.B., and Hill, M.N. (2011, August 15). Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 35(7), 1575-85. Retrieved from <http://www.sciencedirect.com/science/article/pii/S0278584610004380>.
- Haj-Dahmane, S., and Shen, R.Y. (2014, October 29). Chronic stress impairs α 1-adrenoceptor-induced endocannabinoid-dependent synaptic plasticity in the dorsal raphe nucleus. *The Journal of Neuroscience*, 34(44), 14560-14570. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212061/>.
- Hill, M.N., and Gorzalka, B.B. (2009, December). The endocannabinoid system and the treatment of mood and anxiety disorders. *CNS & Neurological Disorders Drug Targets*, 8(6), 451-8. Retrieved from <http://www.eurekaselect.com/93571/article>.
- Hill, M.N., Hillard, C.J., Bambico, F.R., Patel, S, Gorzalka, B.B., and Gobbi, G. (2009, September). The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. *Trends in Pharmacological Sciences*, 30(9), 484-93. Retrieved from [http://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147\(09\)00121-7?returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0165614709001217%3Fshowall%3Dtrue](http://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147(09)00121-7?returnURL=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0165614709001217%3Fshowall%3Dtrue).
- Hill, M. N., Miller, G. E., Carrier, E. J., Gorzalka, B. B., & Hillard, C. J. (2009). Circulating Endocannabinoids and N-Acyl Ethanolamines Are Differentially Regulated in Major Depression and Following Exposure to Social Stress. *Psychoneuroendocrinology*, 34(8), 1257–1262. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716432/>.
- Ho, W. V., Hill, M. N., Miller, G. E., Gorzalka, B. B., & Hillard, C. J. (2012). Serum contents of endocannabinoids are correlated with blood pressure in depressed women. *Lipids in Health and Disease*, 11, 32. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334711/>.
- Jiang, W., Zhang, Y., Xiao, L., Van Cleemput, J., Ji, S.P., Bai, G., and Zhang, X. (2005, November). Cannabinoids promote embryonic and adult hippocampus neurogenesis and

produce anxiolytic- and antidepressant-like effects. *Journal of Clinical Investigation*, 115(11), 3104-3116. Retrieved

from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1253627/>.

- Smaga, I., Bystrowska, B., Gawliński, D., Pomierny, B., Stankowicz, P., & Filip, M. (2014). Antidepressants and Changes in Concentration of Endocannabinoids and N-Acylethanolamines in Rat Brain Structures. *Neurotoxicity Research*, 26(2), 190–206. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067538/>.
- What Is Depression? (n.d.). National Institute of Mental Health. Retrieved from <https://www.nimh.nih.gov/health/topics/depression/index.shtml>.

Insomnia – Learn More:

- Calik, M.W., Radulovacki, M., and Carley, D.W. (2014, January 1). Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat. *Respiratory Physiology & Neurobiology*, 190, 20-24. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880550/>.
- Cousens, K., and DiMascio, A. (1973). (-)- δ^9 THC as an hypnotic. *Psychopharmacologia*, 33, 355-364. Retrieved from <http://link.springer.com/article/10.1007/BF00437513>.
- Dahl, R.E., Scher, M.S., Williamson, D.E., Robles, N., and Day, N. (1995). A longitudinal study of prenatal marijuana use: Effects on sleep and arousal at age 3 years. *Archives of Pediatrics & Adolescent Medicine*, 149(2), 145-50. Retrieved from <http://store.jamanetwork.com/productDetails.aspx?articleId=517460>.
- Fraser, G.A. (2009). The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). *CNS Neuroscience & Therapeutics*, 15, 84-88. Retrieved from <http://onlinelibrary.wiley.com/doi/10.1111/j.1755-5949.2008.00071.x/pdf>.
- Gates, P.J., Albertella, L., and Copeland, J. (2014, December). The effects of cannabinoid administration on sleep: a systematic review of human studies. *Sleep Medicine Reviews*,

18(6), 477-87. Retrieved

from <http://www.sciencedirect.com/science/article/pii/S1087079214000215>.

- Gorelick, D.A., Goodwin, R.S., Schwilke, E., Schroeder, J.R., Schwoppe, D.M., Kelly, D.L., Ortemann-Renon, C., Bonnett, D., and Huestis, M.A. (2013, September-October). Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers. *The American Journal on Addictions*, 22(5), 510-514. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537525/>.
- Jetley, R., Heber, A., Fraser, G., and Boisvert, D. (2015, January). The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. *Psychoneuroendocrinology*, 51, 585-8. Retrieved from [http://www.psyneuenjournal.com/article/S0306-4530\(14\)00413-2/fulltext](http://www.psyneuenjournal.com/article/S0306-4530(14)00413-2/fulltext).
- Murillo-Rodríguez, E., Palomero-Rivero, M., Millán-Aldaco, D., Arias-Carrión, O., and Drucker-Colín, R. (2011). Administration of URB597, Oleoylethanolamide or Palmitoylethanolamide Increases Waking and Dopamine in Rats. *PLoS ONE*, 6(7), e20766. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136458/>.
- Pava, M.J., Makriyannis, A., and Lovinger, D.M. (2016). Endocannabinoid Signaling Regulates Sleep Stability. *PLoS ONE*, 11(3), e0152473. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816426/>.
- Prasad, B., Radulovacki, M.G., and Carley, D.W. (2013). Proof of Concept Trial of Dronabinol in Obstructive Sleep Apnea. *Frontiers in Psychiatry*, 4, 1. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3550518/>.
- Rueda-Orozco, P.E., Soria-Gomez, E., Montes-Rodriguez, C.J., Perez-Morales, M., and Prospero-Garcia, O. (2010, April 5). Intrahippocampal administration of anandamide increases REM sleep. *Neuroscience Letters*, 473(2), 158-162. Retrieved from <http://www.sciencedirect.com/science/article/pii/S0304394010002284>.
- Santucci, V., Storme, J.J., Soubrie, P., and Le Fur, G. (1996, January). Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by

electroencephalographic spectral and sleep-waking cycle analysis. Life Sciences, 58(6),
PL103-10. Retrieved

from <http://www.sciencedirect.com/science/article/pii/S0024320595023194?via%3Dihub>.

- Sleep Disorders. (2015, December 16). MedlinePlus. Retrieved from <https://www.nlm.nih.gov/medlineplus/sleepdisorders.html>.
- Sleep Disorders. (n.d.). National Sleep Foundation. Retrieved from <https://sleepfoundation.org/sleep-disorders-problems>.
- Sleep disorders. (2014, February 7). Mayo Clinic. Retrieved from <http://www.mayoclinic.org/diseases-conditions/sleep-disorders/basic>.

Fibromyalgia – Learn More:

- Chiari malformation and syringomyelia. (n.d.). Mayo Clinic. Retrieved from <http://www.mayoclinic.org/medical-professionals/clinical-updates/neurosciences/chiari-malformation-syringomyelia>.
- de Souza Nascimento, S., Desantana, J.M., Nampo, F.K., Ribeiro, E.A., da Silva, D.L., Araujo-Junior, J.X., da Silva Almeida, J.R., Bonjardim, L.R., de Souza Araujo, A.A., and Quintans-Junior, L.J. (2013). Efficacy and safety of medicinal plants or related natural products for fibromyalgia: a systematic review. Evidence-Based Complementary and Alternative Medicine, 2013. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687718/>.
- Fibromyalgia. (2014, February 20). Mayo Clinic. Retrieved from <http://www.mayoclinic.org/diseases-conditions/fibromyalgia/basics/definition/con-20019243>.
- Fibromyalgia. (2014, July). National Institute of Arthritis and Musculoskeletal and Skin Diseases. Retrieved from http://www.niams.nih.gov/health_info/fibromyalgia/.
- Fiz., J., Duran, M., Capella, D., Carbonell, J., and Farre, M. (2011, April). Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS One, 6(4). Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080871/>.

- Skrabek, R.Q., Galimova, L., Ethans, K., and Perry, D. (2008, February). Nabilone for the treatment of pain in fibromyalgia. *Journal of Pain*, 9(2), 164-73. Retrieved from [http://www.jpain.org/article/S1526-5900\(07\)00873-5/fulltext](http://www.jpain.org/article/S1526-5900(07)00873-5/fulltext).
- Ste-Marie, P.A., Fitzcharles, M.A., Gamsa, A., Ware, M.A., and Shir, Y. (2012, August). Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. *Arthritis Care & Research*, 64(8), 1202-8. Retrieved from <http://onlinelibrary.wiley.com/doi/10.1002/acr.21732/full>.
- Ware, M.A., Fitzcharles, M.A., Joseph, L., and Shir, Y. (2010, February 1). The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. *Anesthesia and Analgesia*, 110(2), 604-10. Retrieved from <http://journals.lww.com/anesthesia-analgesia/pages/articleviewer.aspx?year=2010&issue=02000&article=00056&type=abstract>.
- Wissel, J., Haydn, T., Muller, J., Brenneis, C., Berger, T., Poewe, W., and Schelosky, L.D. (2006, October). Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. *Journal of Neurology*, 253(10), 1337-41. Retrieved from <http://link.springer.com/article/10.1007%2Fs00415-006-0218-8>.